ArticleNature communications2026

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.

Zev A Wainberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.